Acceleron Pharma Inc (XLRN) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.59 earnings per share for the quarter, missing the analyst consensus estimate by $-0.07. Analysts had a consensus of $-0.52. The company posted revenue of $3.20 million in the period, compared to analysts expectations of $3.66 million. The company’s revenue was down -43.9% compared to the same quarter last year.
Acceleron Pharma Inc closed down -1.39 points or -4.04% at $33.01 with 3,29,886 shares getting traded on Tusday. Post opening the session at $34.38, the shares hit an intraday low of $32.5 and an intraday high of $35.1 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jul 6, 2016, Matthew L Sherman (EVP & Chief Medical Officer) sold 26,000 shares at $34.54 per share price. According to the SEC, on Jul 6, 2016, Steven D Ertel (EVP & Chief Operating Officer) sold 32,270 shares at $33.93 per share price. On Jul 6, 2016, Kevin F Mclaughlin (SVP, CFO and Treasurer) sold 25,300 shares at $34.66 per share price, according to the Form-4 filing with the securities and exchange commission.
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s research focuses on key natural regulators of cellular growth and repair particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how including its knowledge of the TGF-b superfamily and its internal protein engineering and manufacturing capabilities the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.